Neuromyelitis Optica Clinical Consortium (NMOCC) Clinical Database Development for Neuromyelitis Optica Spectrum Disorders

Overview

About this study

The primary objective is of this protocol to create a database of NMO patient information that can be queried to address specific scientific questions.  The first series of questions will focus on the clinical characteristics and course of the disease.  For example, sex ratio, ethnicity, and age of onset will be described for NMOSD as a whole and amongst the different diagnostic subcategories.  A main question of whether NMO-IgG seropositive patients differ with respect to disease activity compared with seronegative patients and exploratory multivariable analyses of the natural history will be conducted

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

The inclusion criteria for this study are the following:

  1. The patient must satisfy diagnostic criteria for at least one of the following diseases:
    1. Neuromyelitis optica spectrum disorders—Diagnostic criteria include history or evidence of optic neuritis and longitudinally extensive transverse myelitis without symptomatic involvement of the brain by history or MRI.
      1. NMO seropositive patients are those who have a circulating antibody, NMO-IgG, against aquaporin-4.
      2. NMO seronegative patients are those who likely have NMO but do not test positive for the NMO-IgG
      3. Any clinical syndrome associated with positive NMO-IgG
    2. Bilateral optic neuritis—Diagnostic criteria include history or evidence of optic neuritis in both eyes without symptomatic involvement of the brain by history.
    3. Longitudinally extensive transverse myelitis—Diagnostic criteria include history or evidence of longitudinally extensive inflammation across at least three continuous vertebral lengths of the spinal cord without symptomatic involvement of the brain by history or MRI.
    4. Recurrent transverse myelitis—Diagnostic criteria include history or evidence of inflammation in the spinal cord that recurred at least 3 months apart with evidence of remission in between events.
    5. Monophasic transverse myelitis—Diagnostic criteria include history of evidence of inflammation in one focal area of the spinal cord without recurrence or symptomatic involvement of the brain by history or MRI.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Dean Wingerchuk, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Anne Allen

(480) 342-6054

Allen.Anne@mayo.edu

More information

Publications

Publications are currently not available